Humacyte's Human Acellular Vessel Shows Long Term Benefit In Hemodialysis Patients

Humacyte Inc HUMA announced five-year data from a Phase 2 trial of Human Acellular Vessel (HAV) for arteriovenous (AV) access in hemodialysis.

  • In the Phase 2 long-term follow-up data, the HAV was observed to provide routine and functional hemodialysis access for patients with end-stage renal disease who require dialysis three times a week. 
  • At month 60, patency allowing for reliable dialysis access cannulation was estimated at 58.2% of evaluable patients after censoring for deaths and withdrawals. 
  • While there was no comparator in this Phase 2 trial, historical reports of arteriovenous fistula, currently the most prevalent method of providing hemodialysis access, indicate an approximately 30% functional patency of evaluable patients at five years. 
  • Related: After NASDAQ Debut, Humacyte's Investor Adds $25M Infusion.
  • In addition, no infections of the HAV were reported during the five-year follow-up period, with the HAV being well-tolerated and non-immunogenic.
  • The Company is currently conducting a Phase 3 trial in up to 240 dialysis patients to assess the usability of the HAV for dialysis at six and 12 months compared to autogenous fistulas. 
  • Human Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels under development for vascular repair, reconstruction, and replacement.
  • Price Action: HUMA shares are trading 3.66% higher at $5.95 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!